268 related articles for article (PubMed ID: 27412241)
1. Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models.
Campion CA; Soden D; Forde PF
BMC Cancer; 2016 Jul; 16():462. PubMed ID: 27412241
[TBL] [Abstract][Full Text] [Related]
2. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity.
Gujar SA; Marcato P; Pan D; Lee PW
Mol Cancer Ther; 2010 Nov; 9(11):2924-33. PubMed ID: 20978162
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134
[TBL] [Abstract][Full Text] [Related]
4. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
6. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
7. Modulation of specific active immunization against murine melanoma using recombinant cytokines.
Stidham KR; Ricci WM; Vervaert C; Abdel-Wahab Z; Seigler HF; Darrow TL
Surg Oncol; 1996; 5(5-6):221-9. PubMed ID: 9129134
[TBL] [Abstract][Full Text] [Related]
8. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.
Xu X; Sun Q; Yu X; Zhao L
Virus Res; 2017 Apr; 233():35-41. PubMed ID: 28286036
[TBL] [Abstract][Full Text] [Related]
9. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine.
Igoucheva O; Grazzini M; Pidich A; Kemp DM; Larijani M; Farber M; Lorton J; Rodeck U; Alexeev V
Gene Ther; 2013 Sep; 20(9):939-48. PubMed ID: 23552473
[TBL] [Abstract][Full Text] [Related]
10. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits.
Seledtsova GV; Shishkov AA; Kaschenko EA; Goncharov AG; Gazatova ND; Seledtsov VI
Eur J Dermatol; 2016 Apr; 26(2):138-43. PubMed ID: 27026566
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus oncolytic vaccine therapy in melanoma.
Sivendran S; Pan M; Kaufman HL; Saenger Y
Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins C; Simpson GR; Rogers W; Relph K; Harrington K; Melcher A; Roulstone V; Kyula J; Pandha H
Cancer Gene Ther; 2018 Jun; 25(5-6):148-160. PubMed ID: 29720674
[TBL] [Abstract][Full Text] [Related]
14. Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses.
Seledtsova GV; Shishkov AA; Kaschenko EA; Seledtsov VI
Biomed Pharmacother; 2016 Oct; 83():1247-1252. PubMed ID: 27565847
[TBL] [Abstract][Full Text] [Related]
15. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice.
Zhao F; Dou J; Wang J; Chu L; Tang Q; Wang Y; Li Y; Cao M; Hu W; Hu K; Feng He X; Gu N
Immunobiology; 2010; 215(2):89-100. PubMed ID: 19457579
[TBL] [Abstract][Full Text] [Related]
16. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.
Lopes A; Feola S; Ligot S; Fusciello M; Vandermeulen G; Préat V; Cerullo V
J Immunother Cancer; 2019 Jul; 7(1):174. PubMed ID: 31291991
[TBL] [Abstract][Full Text] [Related]
18. Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.
Chen X; Liu Z; Huang Y; Li R; Zhang H; Dong S; Ge C; Zhang Z; Wang Y; Wang Y; Xue Y; Li Z; Song X
Autoimmunity; 2014 Feb; 47(1):46-56. PubMed ID: 24191684
[TBL] [Abstract][Full Text] [Related]
19. NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.
Bar-On Y; Charpak-Amikam Y; Glasner A; Isaacson B; Duev-Cohen A; Tsukerman P; Varvak A; Mandelboim M; Mandelboim O
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724773
[TBL] [Abstract][Full Text] [Related]
20. Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine.
Zhao F; Zhang R; Wang J; Wu D; Pan M; Li M; Guo M; Dou J
Int Immunopharmacol; 2017 Nov; 52():238-244. PubMed ID: 28950176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
